Market closedNon-fractional
Organogenesis/ORGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Ticker
ORGO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Canton, United States
Employees
862
Website
organogenesis.com
Organogenesis Metrics
BasicAdvanced
$427M
Market cap
75.88
P/E ratio
$0.04
EPS
1.60
Beta
-
Dividend rate
Price and volume
Market cap
$427M
Beta
1.6
Financial strength
Current ratio
2.744
Quick ratio
2.232
Long term debt to equity
34.676
Total debt to equity
41.801
Interest coverage (TTM)
7.09%
Management effectiveness
Return on assets (TTM)
2.28%
Return on equity (TTM)
2.15%
Valuation
Price to earnings (TTM)
75.877
Price to revenue (TTM)
0.972
Price to book
1.53
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
62.161
Growth
Revenue change (TTM)
-5.62%
Earnings per share change (TTM)
-58.86%
3-year revenue growth (CAGR)
4.73%
3-year earnings per share growth (CAGR)
-50.99%
What the Analysts think about Organogenesis
Analyst Ratings
Majority rating from 3 analysts.
Organogenesis Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$110M
10.34%
Net income
-$2.1M
320.00%
Profit margin
-1.91%
282.00%
Organogenesis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.04
$0.02
-
-$0.02
-
Expected
$0.03
$0.01
$0.01
-$0.03
-$0.01
Surprise
60.00%
300.00%
-
-25.00%
-
Organogenesis News
AllArticlesVideos
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
GlobeNewsWire·2 weeks ago
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
GlobeNewsWire·2 months ago
Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organogenesis stock?
Organogenesis (ORGO) has a market cap of $427M as of July 27, 2024.
What is the P/E ratio for Organogenesis stock?
The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 75.88 as of July 27, 2024.
Does Organogenesis stock pay dividends?
No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Organogenesis dividend payment date?
Organogenesis (ORGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Organogenesis?
Organogenesis (ORGO) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Organogenesis stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.